Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

Researchers identify new target for cystic fibrosis

The lab of Kevin Foskett, PhD, the Isaac Ott Professor of Physiology at the University of Pennsylvania School of Medicine, has found a possible new target for fighting cystic fibrosis (CF) that could compensate for the lack of a functioning ion channel in affected CF-related cells. Their finding appears in the Journal of Clinical Investigation.

18 Sep 2010

Aradigm to present Phase 1 studies of inhaled liposomal ciprofloxacin at 2010 ERS Congress

Aradigm Corporation today announced it is presenting data on September 22, 2010, from its Phase 1 studies at the ERS Annual Congress in Barcelona, Spain. The podium presentation elaborates on the pharmacokinetic parameters of ciprofloxacin in the blood and sputum samples that were observed in the healthy volunteers and non-cystic fibrosis bronchiectasis (BE) patients.

17 Sep 2010

Inspire Pharmaceuticals to present denufosol tetrasodium therapy data at ERS Annual Congress

Inspire Pharmaceuticals, Inc. announced today that data will be presented on denufosol tetrasodium, an investigational therapy for cystic fibrosis (CF), during oral and poster presentations at the European Respiratory Society (ERS) Annual Congress September 18 - 22, 2010 in Barcelona, Spain.

17 Sep 2010

Study finds new therapeutic target for polycystic kidney disease

In work suggesting a new approach to treating polycystic kidney disease (PKD), a leading cause of kidney failure, researchers at Children's Hospital Boston were able to block the formation of fluid-filled cysts, the hallmark of the disease, in a mouse model. Their findings, using a compound that inhibits a receptor known as c-Met, will be published in the September 13th online edition of the Journal of Clinical Investigation.

14 Sep 2010

Capstone Therapeutics reaches overall progress in AZX100 Phase 2a clinical trials for keloid scarring

Capstone Therapeutics announced today that participating subjects have reached the planned twelve-month timepoint in the first of its two ongoing AZX100 Phase 2a clinical trials in keloid scarring. Data analysis for these subjects is underway. Per protocol and the original clinical development plan, results of the two keloid scarring trials will be pooled for analytical purposes and are scheduled for release during 4Q2010.

14 Sep 2010

InterMune's development program for pirfenidone, IPF to be presented at Annual Congress of ERS

InterMune, Inc. today announced that four oral presentations related to the company's development program for pirfenidone and idiopathic pulmonary fibrosis will be presented at the Annual Congress of the European Respiratory Society, to be held September 18-22 in Barcelona, Spain.

13 Sep 2010

Pro-Pharmaceuticals engages Numoda Corporation to optimize DAVANAT Phase III clinical trial

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that it has engaged the Numoda Corporation, a leading information, process and logistics management company, to oversee the Phase III clinical trial of DAVANAT and 5-FU compared with the standard of care in the treatment of patients with advanced, metastatic colorectal cancer.

13 Sep 2010

NanoBio Corporation to present Nanoemulsion Phase I clinical trial data at ICAAC Conference

NanoBio Corporation today announced it will present data from two separate Phase 1 clinical trials at the 2010 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place in Boston, Mass. from Sept. 12-15.

13 Sep 2010

Lantheus Medical Imaging supports FDA action to ensure appropriate use of gadolinium-based contrast agents

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, supports the U.S. Food and Drug Administration's (FDA) announcement requiring safety-related label changes for all gadolinium-based contrast agents to highlight the rare and potentially fatal condition known as nephrogenic systemic fibrosis (NSF).

10 Sep 2010

GBCAs carry new warnings on their labels about risk of NSF: FDA

The U.S. Food and Drug Administration is requiring that gadolinium-based contrast agents (GBCAs) carry new warnings on their labels about the risk of a rare and potentially fatal condition known as nephrogenic systemic fibrosis, if the drug is administered to certain patients with kidney disease.

10 Sep 2010

Translational Research issue focuses field of stem cell research, therapy

The use of stem cells for research and their possible application in the treatment of disease are hotly debated topics. In a special issue of Translational Research published this month an international group of medical experts presents an in-depth and balanced view of the rapidly evolving field of stem cell research and considers the potential of harnessing stem cells for therapy of human diseases including cardiovascular diseases, renal failure, neurologic disorders, gastrointestinal diseases, pulmonary diseases, neoplastic diseases, and type 1 diabetes mellitus.

10 Sep 2010

DARA BioSciences presents KRN5500 study results at World Congress on Pain

DARA BioSciences announced today that it presented study results from its Phase 2 multicenter, placebo controlled, double-blind, randomized dose escalation study for KRN5500 at the 13th World Congress on Pain held recently in Montreal.

9 Sep 2010

Phase 3 REALIZE study shows milestone in treatment development for hepatitis C

Vertex Pharmaceuticals Incorporated today announced that 65% of people overall achieved a sustained viral response (SVR or viral cure) with a telaprevir-based regimen in the pivotal Phase 3 REALIZE study, as compared to 17% of people in the control arm who received pegylated-interferon and ribavirin alone.

8 Sep 2010

Researchers discover tolerance mechanism in chronic morphine treatment

Researchers from Mount Sinai School of Medicine have discovered a major mechanism underlying the development of tolerance to chronic morphine treatment. The discovery may help researchers find new therapies to treat chronic pain, and reduce tolerance and side effects associated with morphine use. The findings are published in the July 20th issue of Science Signaling.

8 Sep 2010

Promedior initiates PRM-151 Phase 2a clinical study in prevention of scarring post glaucoma filtration surgery

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today that it has initiated a Phase 2a clinical study of PRM-151 to evaluate the efficacy, safety, and tolerability of PRM-151 in preventing post-surgical scarring in glaucoma patients following glaucoma filtration surgery. There currently are no approved drugs for preventing post-surgical scarring in glaucoma, and there are no approved anti-fibrotic drug therapies in the U.S. or Europe for any fibrotic disease.

7 Sep 2010

Fundraising events in September in support of pulmonary fibrosis research

The Pulmonary Fibrosis Foundation (PFF) today announced its September schedule of fundraising events as part of its ongoing campaign to support the efforts of patients and families to raise new funds for pulmonary fibrosis (PF) research.

4 Sep 2010

Fibrosis with inflammation after one year predicts risk of long-term kidney transplant failure

Kidney transplants that show a combination of fibrosis (scarring) and inflammation after one year are at higher risk of long-term transplant failure, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

3 Sep 2010

Research finds immune system mechanism to minimize collateral damage

A study published today in the journal Science shows how our bodies try to minimise potential 'collateral damage' caused by our immune system when fighting infection. The research may also provide new clues to why cigarette smoke is a significant risk factor for developing diseases of the lung such as chronic bronchitis and emphysema.

3 Sep 2010

Cigarette smoke inhibits LTA4H enzyme, regulates body's response to inflammation: Study

Cigarette smoke shuts off a key enzyme in airways that regulates the body's response to inflammation, according to findings from the University of Alabama at Birmingham published online today at Science Express.

3 Sep 2010

NIH awards $1.2 million EUREKA grant to study protein misfolding

Three University of Massachusetts Amherst scientists have received a four-year, $1.2 million EUREKA grant from the U.S. National Institutes of Health (NIH) to study folding and misfolding of secretory proteins in the cell's protein factory, the endoplasmic reticulum, where misfolding can lead to diseases such as cystic fibrosis and liver cirrhosis.

3 Sep 2010

Fibrosis News and Research

Further Reading

Researchers identify new target for cystic fibrosis

Aradigm to present Phase 1 studies of inhaled liposomal ciprofloxacin at 2010 ERS Congress

Inspire Pharmaceuticals to present denufosol tetrasodium therapy data at ERS Annual Congress

Study finds new therapeutic target for polycystic kidney disease

Capstone Therapeutics reaches overall progress in AZX100 Phase 2a clinical trials for keloid scarring

InterMune's development program for pirfenidone, IPF to be presented at Annual Congress of ERS

Pro-Pharmaceuticals engages Numoda Corporation to optimize DAVANAT Phase III clinical trial

NanoBio Corporation to present Nanoemulsion Phase I clinical trial data at ICAAC Conference

Lantheus Medical Imaging supports FDA action to ensure appropriate use of gadolinium-based contrast agents

GBCAs carry new warnings on their labels about risk of NSF: FDA

Translational Research issue focuses field of stem cell research, therapy

DARA BioSciences presents KRN5500 study results at World Congress on Pain

Phase 3 REALIZE study shows milestone in treatment development for hepatitis C

Researchers discover tolerance mechanism in chronic morphine treatment

Promedior initiates PRM-151 Phase 2a clinical study in prevention of scarring post glaucoma filtration surgery

Fundraising events in September in support of pulmonary fibrosis research

Fibrosis with inflammation after one year predicts risk of long-term kidney transplant failure

Research finds immune system mechanism to minimize collateral damage

Cigarette smoke inhibits LTA4H enzyme, regulates body's response to inflammation: Study

NIH awards $1.2 million EUREKA grant to study protein misfolding

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News